Home' Australian Pharmacist : Australian Pharmacist April 2015 Contents Australian Pharmacist April 2015 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month (15,500
pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than 10,000
pharmacists – a typical monthly article receives 3000 plus assessments,
with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9547 3001
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Answers for crossword on page 71.
Across: 1. Grandchildren, 6. Reflux, 8. Po,
9. Myalgia, 11. Toe, 12. Tendon, 13. Fish,
17. Sharp, 20. Statin, 21. Micro, 22. Gout,
23. Onset, 24. Dairyman.
Down: 2. Amino, 3. Herbal, 4. Bursitis, 5.
Common, 7. Knee, 8. Pain, 10. Arthralgia,
14. Insomnia, 15. Monitor, 16. Joint, 18.
Hip, 19. Rained.
Boehringer Ingelheim has announced
that idarucizumab* has been submitted
for approval of marketing authorisation
to the European Medicines Agency
(EMA), the US Food and Drug
Administration (FDA) and Health
Canada. The submission is for use in
patients who require rapid reversal of
the anticoagulant effect of dabigatran,
the active ingredient in Pradaxa.
Professor Jörg Kreuzer, Vice
President Medicine Therapeutic Area
Cardiovascular, Boehringer Ingelheim
said: ‘The submissions for idarucizumab
mark the first regulatory submissions
for a specific reversal agent to a novel
oral anticoagulant. Our discovery and
development of idarucizumab in‐
house is an example of our company’s
dedication to the evolution and
innovation of anticoagulation care.
Idarucizumab is being developed to
provide physicians with a specifically
targeted reversal agent for Pradaxa
patients in rare emergency situations,’
The submissions to the EMA, FDA and
Health Canada are based on the results
from clinical trials of idarucizumab
in volunteers, including elderly and
renally impaired individuals. Phase I data
showed an immediate, complete and
sustained reversal of the anticoagulant
effect of dabigatran following the
administration of idarucizumab and no
pro‐thrombotic effect. The submissions
also include first interim data from
the ongoing RE-VERSE AD study, an
ongoing global Phase III patient
study in which Boehringer Ingelheim
continues to evaluate idarucizumab in
patients treated with Pradaxa who need
emergency intervention, or experience
an uncontrolled or life‐threatening
*Idarucizumab is the recommended International
Nonproprietary Name. It is in late-stage
development and has not yet been approved for
Glucojel has added mint flavoured
jelly beans to its range, making it
the first mint jelly bean available in
Australia. Tapping into the rapidly
growing mint category, Glucojel Jelly
Beans has launched a 70gm Mint
packet. Glucojel Mint is made with
all natural colours and is available
from all wholesalers. Glucojel Mint is
being promoted through Lightning
Brokers who also have a range of
display material as well as give away
Following on from the success of the
new Glucojel Mint, Gold Cross will be
transitioning the current range over to
all natural colours during the next six
months, to maintain a consistent level of
quality across the range.
Links Archive Australian Pharmacist March 2015 Australian Pharmacist May 2015 Navigation Previous Page Next Page